Tac-3
is back! Parnell to reassume sales, marketing & distribution of Tac-3 Today's Date -- Parnell Pharmaceuticals has announced that effective March 1, 1997, it will reassume the sales, marketing & distribution of its Tac-3®. Tac-3 is an injectable steroid for the treatment of psoiraisis, and was previously marketed for the last ten years under a license agreement by Allergan Pharmaceuticals in Irvine, California. Parnell Pharmaceuticals received an NDA (New Drug Approval) from the FDA in 1987. It was one of 22 new drugs approved that year by the Food & Drug Administration. For More Information Contact: Parnell Pharmaceuticals,
Inc. |